Month: December 2021

ICER To Look at Gene Therapy for Thalassemia

The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of betibeglogene autotemcel (Zynteglo/LentiGlobin, bluebird bio) for the treatment of beta thalassemia. An FDA decision on betibeglogene autotemcel is expected in mid-2022.  ICER is inviting public comment on its initial Draft Scoping Document, which details […]

Read more


Secured By miniOrange